Skip to content

DBV Technologies

US · DBVT #3611 by market cap Listed 2015
9.77 -0.21 -2.10%
Live - 5344 symbols - heartbeat 41s ago · 2026-10-08 08:01
Pre-market 9.73 -0.41%
After-hours 9.32 -4.61%
Overnight 9.62 -1.54%
Market cap
614.03M
P/B
3.83
EPS
-5.25
Reader sentiment Are you bullish or bearish on DBVT?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.83 Expensive vs history 70th percentile
5-year average 7.79 · #343 of 513 in Biotechnology
P/E ratio -2.79 In line with history 34th percentile
5-year average -2.33 · forward -3.66
P/S ratio --
5-year average 222.02 · forward 16.90

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
DBV Technologies (DBVT) 614.03M -2.79 3.83 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value10.79 Economic moatNone UncertaintyVery High

Trading 10.5% below Morningstar's fair value estimate.

Fair value

DBV Technologies SA receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $10.79 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 0.8 ranks in the bottom 20% compared with global peers. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be undervalued.

On a different note, the firm's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:01:50 · For reference only, not investment advice and not tailored to your situation.